Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving) allergy remedy, by over 400%.
“Look, no one’s more frustrated than me,” Mylan Chief Executive Heather Bresch declared on CNBC.
22:33 Allergan to pay $15 million over failing to disclose merger talks12
21:40 HP Enterprise to buy cloud software company SimpliVity14
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
12:03 Will Trump's State Pick Tillerson Serve the U.S. or Exxon Mobil?19